Webcast

All Hands: Integrating a Team Approach to Risk-Benefit Individualization of Rheumatoid Arthritis and Psoriatic Arthritis Therapy

Launch Date
01/27/2021
Credit Amount
0.00 Expired
Credit Expires
01/27/2022

Faculty

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Weill Cornell Medicine
Attending Rheumatologist and Co-Director, Clinic for Inflammatory Arthritis, Hospital for Special Surgery, New York, NY
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Allan Gibofsky, MD, JD, MACR, FACP, FCLM, serves as Professor of Medicine in the Department of Healthcare Policy and Research at Weill Cornell Medicine. Dr Gibofsky is an attending physician and rheumatologist at the Hospital for Special Surgery, where he is Co- Director of the Clinic for Inflammatory Arthritis. He received his undergraduate degree from Brooklyn College of the City University of New York, his medical degree from Weill Medical College of Cornell University, and his law degree from Fordham University School of Law. He did his internship in pathology, followed by a residency in medicine at New York Hospital. He completed a fellowship in rheumatology/immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr Gibofsky has authored or co-authored numerous papers and textbook chapters, primarily on rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular, for his basic and clinical studies on rheumatic fever.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and is a recipient of its Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees and was Chair for Professional Education. Dr Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He served as President of The American College of Rheumatology and was recently named a Master. Dr Gibofsky is a Jonas Salk Scholar of the City University and an Alumnus of the Year of Brooklyn College. He is past President of the American College of Legal Medicine and is past Chair of the American Board of Legal Medicine. Dr Gibofsky is past Chair of the Arthritis Advisory Committee of the Food and Drug Administration and continues as a special consultant to that committee.

Philip J. Mease, MD, MACR
Director, Rheumatology Clinical Research, Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine, Seattle, WA
Philip J. Mease, MD, MACR

Dr. Mease received undergraduate and medical degrees from Stanford University and completed residency in internal medicine and fellowship in rheumatology at the University of Washington. He directs the Rheumatology Research Division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His major research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA). His work includes research on disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. Dr. Mease has authored over 490 journal articles, numerous abstracts, and book chapters. He is past president, founding organizer, and current treasurer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and a member of its Collaborative Research Network (CRN) steering committee. He is also a member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Dr. Mease is active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization as co-chair of the PsA and chronic pain working groups and as a steering committee member. He is the Scientific Director of the PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Dr. Mease is co-chair of the PsA task force of the National Psoriasis Foundation, which in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Although rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with irreversible joint damage and physical disability, remission is now an achievable goal for the majority of patients, owing to advances in early diagnosis, new therapies, and improved treatment strategies.

This CME Outfitters Live and OnDemand webcast focuses on integrating a multidisciplinary approach to treating PsA and RA through case-based learning, with expert faculty discussing management strategies and how to integrate shared decision-making (SDM) into practice to facilitate appropriate treatment selection and empower patients.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Develop short- and long-term therapeutic strategies that account for risk-benefit in the management of patients with RA or PsA.
  • Integrate a multidisciplinary approach in the treatment of patients with PsA.
  • Incorporate SDM into the selection of appropriate treatments for patients with RA or PsA.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Describe short- and long-term therapeutic strategies for managing patients with RA and PsA.
  • Integrate a multidisciplinary approach in the treatment of patients with PsA.
  • Identify ways to incorporate SDM into the selection of appropriate treatments for patients with RA or PsA.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Rheumatologists, dermatologists, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-002-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Mease reports he receives grants from AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is a consultant for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is on the speakers bureau for: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; Genentech; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Jeffrey Helfand, DO (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Susan Perry (planning committee)
  • Jan Perez (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-002-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

TV-124-012721-02

All Hands: Integrating a Team Approach to Risk-Benefit Individualization of Rheumatoid Arthritis and Psoriatic Arthritis Therapy
Event Date: 01/27/2021